Skip to main content

María M. Corrada, ScM, ScD at AAIC 2021

By Commentary, Community Events, In the News

Related posts: 5TH ANNUAL HUNTINGTON’S DISEASE EDUCATIONAL SYMPOSIUM 5TH ANNUAL HUNTINGTON’S DISEASE EDUCATIONAL SYMPOSIUM SATURDAY, OCTOBER 3rd, 2020, 1:00 – 3:00 PM   Join us for the 2020 Huntington’s Disease Educational Symposium! Due to health concerns over the current COVID-19 pandemic, this year we will be hosting a “virtual” educational symposium. There is no cost to participate, but you must… Sex differences in hallmarks of Alzheimer’s disease: new study finds faster tau accumulation in female brains Contributed by Ashley A. Keiser, PhD A new study from researchers in Sweden published in Brain finds faster accumulation of a major hallmark of Alzheimer’s disease, neurofibrillary…

Read More

UCI MIND Director speaks on AAIC panel about impact and ethics of Aduhelm approval

By Commentary, In the News

Related posts: PODCAST: Helping Others Through Acceptance UCI MIND Leadership Council Member, Steve O’Leary, discusses his journey with Alzheimer’s disease on Voices of Resilience hosted by Rick Milenthal. Steve changed his life, sold his business, and altered his priorities when his wife of 40 years was diagnosed with early onset Alzheimer’s. After losing Patty just over three years ago,… 5TH ANNUAL HUNTINGTON’S DISEASE EDUCATIONAL SYMPOSIUM 5TH ANNUAL HUNTINGTON’S DISEASE EDUCATIONAL SYMPOSIUM SATURDAY, OCTOBER 3rd, 2020, 1:00 – 3:00 PM   Join us for the 2020 Huntington’s Disease Educational Symposium! Due to health concerns over the current COVID-19 pandemic, this year we will be hosting…

Read More

David Sultzer, MD & others show clinical benefit of pimavanserin in AD

By Carousel Slider, Commentary, In the News

UCI MIND professor, David Sultzer, MD, and other investigators show a clinical benefit of an investigational antipsychotic drug, pimavanserin in reducing behavioral symptoms related to Alzheimer’s disease. Related posts: UCI MIND awarded $14.4 million NIH grant to continue critical Alzheimer’s disease research, education UCI MIND, the Institute for Memory Impairments and Neurological Disorders at UCI, has been awarded a $14.4 million grant from the National Institute on Aging, one of the National Institutes of Health, to sustain critical research and education as Orange County’s only Alzheimer’s Disease Research Center. The NIA funds only… This brain protein may put the brakes…

Read More

Dr. Vivek Swarup featured on ALZFORUM

By Commentary, In the News

UCI MIND researcher, Dr. Vivek Swarup is gaining significant attention for his work on glial cell gene expression in AD. His lab’s research, published in Nature Genetics 2 weeks ago was recently featured on the heavily trafficked Alzheimer’s research website, Alzforum.com – a testament to the impact his research has on the broader AD community. Dr. Swarup used prefrontal cortex brain tissue from UCI ADRC brain donors to examine differences in glial cell gene transcription between healthy and AD brains.   He found that the areas in the DNA above important AD risk genes, responsible for expressing those genes, were different…

Read More

Sept. 10th Virtual Alzheimer’s Research Conference #AlzAngles: Thomas Lane, PhD

By Commentary, Community Events

Sept. 10th Virtual Alzheimer’s Research Conference #AlzAngles: Dr. Thomas Lane will discuss the impact of viral infections, like COVID-19, on Alzheimer’s disease. Register for free: https://conference.mind.uci.edu/register Related posts: Tackling Dementia with Technology Thank you for attending our first-ever virtual research conference in partnership with Alzheimer’s Orange County. If you missed the livestream on September 10, you can access the recordings, as well as videos from past conferences, on our website: mind.uci.edu/events/conference  A special thank you to this year’s sponsors:… CARE Brain Trust Meeting Contributed by the CARE Registry: It’s time for our very first annual CARE Brain Trust meeting! This…

Read More

Aducanumab update

By Carousel Slider, Commentary, In the News

Contributed by Joshua Grill, PhD and Jason Karlawish, MD UCI MIND Director Joshua Grill, PhD co-authored an article in Nature Reviews Neurology about the FDA’s decision on Aduhelm. Read more on this below: Since the FDA approved Aduhelm (aducanumab) on June 7, there has been considerable conversation, debate, and even backlash about the decision. It may seem difficult to keep up. Here is a recap of some of the most recent important events. The FDA granted Aduhelm what is known as “accelerated approval.” This means that the approval did not indicate that the drug has been adequately shown to benefit…

Read More

New Mouse Model Provides 1st Platform to Study Late-Onset Alzheimer’s

By Carousel Slider, Commentary, In the News

UCI School of Biological Sciences Dean Frank LaFerla is co-senior author of a study involving a new genetically engineered mouse model that, unlike its predecessors, is based on the most common form of Alzheimer’s disease. This could help lead to major strides in the fight to end this deadly disease! Dean LaFerla discusses his findings in a new podcast: https://www.bio.uci.edu/frank-laferla-podcast/ Related posts: FLASH radiation therapy can help treat cancer without neurocognitive side effects, study finds FLASH radiation therapy, also called FLASH-RT, can eliminate the debilitating side effects associated with traditional radiation therapy by delivering the same dose in tenths of…

Read More

Swarup Lab research published in Nature Genetics

By Carousel Slider, Commentary, In the News

Contributed by Vivek Swarup, PhD The brain is made up of billions of cells that are tightly coordinated in complex neural circuitry and are ultimately responsible for manifesting our memories, emotions, and personalities: the very essence of being human. Alzheimer’s Disease (AD) is one of the most prevalent neurodegenerative disorders worldwide and results in cognitive decline and memory loss, and we presently do not have effective treatments for AD. There is a pressing need to deepen our understanding of AD, and by studying how individual cells are changing in disease, or identifying those that are resilient to such changes, we…

Read More

UCI student selected for prestigious research program

By Commentary, In the News

Leslie Vazquez-Rangel, a fourth-year undergraduate at UCI was recently selected to participate in the prestigious Minority Access to Research Careers (MARC) Program, an NIH funded training grant that is awarded to only 640 students across the US each year. The program will allow a select few PhD-bound honors students like Leslie to engage in meaningful research under the guidance of world-renowned professors.  Leslie will spend the next year working with Dr. Elizabeth Head, a professor in the Department of Pathology to study the link between Down syndrome and Alzheimer’s disease. To learn more about Leslie and the incredible research being done in Dr. Head’s lab, visit https://sites.mind.uci.edu/headlab…

Read More

A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it?

By Carousel Slider, Commentary, In the News

A crucial, overlooked question on the new Alzheimer’s drug: When should patients stop taking it? STAT News – June 24, 2021 “When we enroll families in studies of treatments like aducanumab, we try to educate them that they should not expect large improvements in cognition or function,” Joshua Grill, director of the Institute for Memory Impairments and Neurological Disorders at the University of California, Irvine, said in an email to STAT. The drug can’t stop disease progression, only potentially slow it, a change that he warns would likely be imperceptible. “If we can’t expect families to know if the drug…

Read More